Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) CEO Quang Pham sold 3,666 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $3.58, for a total value of $13,124.28. Following the transaction, the chief executive officer owned 132,715 shares in the company, valued at approximately $475,119.70. This trade represents a 2.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Cadrenal Therapeutics Stock Performance
Cadrenal Therapeutics stock opened at $3.10 on Thursday. Cadrenal Therapeutics, Inc. has a 52 week low of $3.02 and a 52 week high of $14.64. The stock has a market capitalization of $8.90 million, a P/E ratio of -0.55 and a beta of 1.59. The stock has a fifty day moving average of $4.95 and a 200-day moving average of $6.50.
Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.47. On average, research analysts forecast that Cadrenal Therapeutics, Inc. will post -5.52 earnings per share for the current year.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on CVKD
Institutional Investors Weigh In On Cadrenal Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in Cadrenal Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after acquiring an additional 1,818 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in Cadrenal Therapeutics during the 3rd quarter worth $103,000. Citadel Advisors LLC bought a new stake in Cadrenal Therapeutics during the 3rd quarter worth $274,000. Finally, DRW Securities LLC bought a new stake in Cadrenal Therapeutics during the 4th quarter worth $171,000. Institutional investors own 7.92% of the company’s stock.
Cadrenal Therapeutics Company Profile
Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Featured Stories
- Five stocks we like better than Cadrenal Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
